

12^a
ACTUALIZACIÓN
en el TRATAMIENTO
LEUCEMIA
AGUDA 2023



del 5 al 7
OCT
2023

Dr. Courtney DiNardo

MD Anderson Cancer Center, Houston, USA

Dr. DiNardo is an academic clinician with a focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups.

Dr. DiNardo has extensive experience in designing and implementing clinical trials in AML and has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).
